BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12241013)

  • 21. Influence of the human paraoxonase polymorphism (PON1 192) on the carotid-wall thickening in a healthy population.
    Dessì M; Gnasso A; Motti C; Pujia A; Irace C; Casciani S; Staffa F; Federici G; Cortese C
    Coron Artery Dis; 1999 Dec; 10(8):595-9. PubMed ID: 10599538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic analysis of Paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians.
    Bonafè M; Marchegiani F; Cardelli M; Olivieri F; Cavallone L; Giovagnetti S; Pieri C; Marra M; Antonicelli R; Troiano L; Gueresi P; Passeri G; Berardelli M; Paolisso G; Barbieri M; Tesei S; Lisa R; De Benedictis G; Franceschi C
    Eur J Hum Genet; 2002 May; 10(5):292-6. PubMed ID: 12082503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of paraoxonase-192 polymorphism with low HDL-cholesterol in coronary artery disease risk.
    Mendonça MI; Dos Reis RP; Freitas AI; Pereira A; Sousa AC; Freitas S; Ornelas I; Freitas C; Brehm A; Araújo JJ
    Rev Port Cardiol; 2010 Apr; 29(4):571-80. PubMed ID: 20734577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of paraoxonase (PON1) status requires more than genotyping.
    Richter RJ; Furlong CE
    Pharmacogenetics; 1999 Dec; 9(6):745-53. PubMed ID: 10634137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification.
    Mackness B; Mackness MI; Arrol S; Turkie W; Durrington PN
    FEBS Lett; 1998 Feb; 423(1):57-60. PubMed ID: 9506841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
    Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
    Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians.
    Campo S; Sardo MA; Trimarchi G; Bonaiuto M; Fontana L; Castaldo M; Bonaiuto A; Saitta C; Bitto A; Manduca B; Riggio S; Saitta A
    Exp Gerontol; 2004 Jul; 39(7):1089-94. PubMed ID: 15236768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease.
    Sanghera DK; Aston CE; Saha N; Kamboh MI
    Am J Hum Genet; 1998 Jan; 62(1):36-44. PubMed ID: 9443862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
    J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of hormone replacement therapy and hepatic lipase polymorphism on serum lipid profiles in postmenopausal Japanese women.
    Somekawa Y; Umeki H; Kobayashi K; Tomura S; Aso T; Hamaguchi H
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4766-70. PubMed ID: 12364471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human paraoxonase 1 gene polymorphisms and the risk of coronary heart disease: a community-based study.
    Watzinger N; Schmidt H; Schumacher M; Schmidt R; Eber B; Fruhwald FM; Zweiker R; Kostner GM; Klein W
    Cardiology; 2002; 98(3):116-22. PubMed ID: 12417809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men.
    Marchesani M; Hakkarainen A; Tuomainen TP; Kaikkonen J; Pukkala E; Uimari P; Seppälä E; Matikainen M; Kallioniemi OP; Schleutker J; Lehtimäki T; Salonen JT
    J Natl Cancer Inst; 2003 Jun; 95(11):812-8. PubMed ID: 12783936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. R/R genotype of human paraoxonase (PON1) is more protective against lipoprotein oxidation and coronary artery disease in Japanese subjects.
    Kuremoto K; Watanabe Y; Ohmura H; Shimada K; Mokuno H; Daida H
    J Atheroscler Thromb; 2003; 10(2):85-92. PubMed ID: 12740482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paraoxonase 1 192 Gln/Arg gene polymorphism and cerebrovascular disease: interaction with type 2 diabetes.
    Koch M; Hering S; Barth C; Ehren M; Enderle MD; Pfohl M
    Exp Clin Endocrinol Diabetes; 2001; 109(3):141-5. PubMed ID: 11409295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm.
    Ito T; Yasue H; Yoshimura M; Nakamura S; Nakayama M; Shimasaki Y; Harada E; Mizuno Y; Kawano H; Ogawa H
    Hum Genet; 2002 Jan; 110(1):89-94. PubMed ID: 11810302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variations of the paraoxonase gene in patients with coronary artery disease.
    Hong SH; Song J; Min WK; Kim JQ
    Clin Biochem; 2001 Sep; 34(6):475-81. PubMed ID: 11676977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus.
    Mackness B; Mackness MI; Arrol S; Turkie W; Julier K; Abuasha B; Miller JE; Boulton AJ; Durrington PN
    Atherosclerosis; 1998 Aug; 139(2):341-9. PubMed ID: 9712341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
    Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
    Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls.
    Gouni-Berthold I; Giannakidou E; Faust M; Berthold HK; Krone W
    Atherosclerosis; 2005 Dec; 183(2):336-41. PubMed ID: 16285997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population.
    Yamada A; Shoji T; Tahara H; Emoto M; Nishizawa Y
    Metabolism; 2001 Jul; 50(7):805-11. PubMed ID: 11436186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.